OR WAIT null SECS
Boehringer Ingelheim’s unbranded adalimumab-adbm biosimilar will be available at an 81% discount to adalimumab (Humira).
Boehringer Ingelheim has announced that its unbranded adalimumab (Humira) biosimilar—adalimumab-adbm—is now available at a low wholesale acquisition cost, according to a press release from the company.1
What’s the Issue?
Boehringer Ingelheim’s unbranded adalimumab-adbm will be available at an 81% discount to adalimumab (Humira), making the medication more affordable and accessible to patients.
Why it Matters
Adalimumab-adbm was originally approved by the FDA in 2017 to treat multiple chronic inflammatory conditions. The medication then became the first and only FDA-approved interchangeable adalimumab (Humira) biosimilar in 2021.2
In Depth Insights
Adalimumab-adbm’s efficacy is supported by VOLTAIRE-X, a phase 3, randomized, comparative clinical trial in which researchers evaluated multiple switches between the biosimilar and reference product.
For more on this issue, check out these articles.